Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Leport

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
The Journal of Antimicrobial Chemotherapy|March 4, 2015
Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severityJean-Philippe Bastard, Soraya Fellahi, Camille Couffignal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2007
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general populationCharlotte Lewden, Genevieve Chene, Philippe Morlat, et al.
The Journal of Infectious Diseases|October 31, 2002
Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR StudyBernard Masquelier, Gilles Peytavin, Catherine Leport, et al.
Plos One|August 23, 2016
Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort StudyMariam Noelie Hema, Tristan Ferry, Michel Dupon, et al.
AIDS Research and Human Retroviruses|September 1, 2011
Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE studyHassan Nazih, François Raffi, Audrey Taïeb, et al.
Antiviral Therapy|February 6, 2004
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up studyMaria Patrizia Carrieri, François Raffi, Charlotte Lewden, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2009
Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort studyTristan Ferry, François Raffi, Fidéline Collin-Filleul, et al.
BMJ Open|November 27, 2012
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapyMaria Patrizia Carrieri, Camelia Protopopescu, Vincent Le Moing, et al.
Therapeutic Drug Monitoring|January 25, 2005
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohortXavier Duval, France Mentré, Claire Lamotte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 16, 2015
Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatmentCatherine Chirouze, Valérie Journot, Vincent Le Moing, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
The Journal of Antimicrobial Chemotherapy|March 4, 2015
Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severityJean-Philippe Bastard, Soraya Fellahi, Camille Couffignal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2007
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general populationCharlotte Lewden, Genevieve Chene, Philippe Morlat, et al.
The Journal of Infectious Diseases|October 31, 2002
Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR StudyBernard Masquelier, Gilles Peytavin, Catherine Leport, et al.
Plos One|August 23, 2016
Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort StudyMariam Noelie Hema, Tristan Ferry, Michel Dupon, et al.
AIDS Research and Human Retroviruses|September 1, 2011
Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE studyHassan Nazih, François Raffi, Audrey Taïeb, et al.
Antiviral Therapy|February 6, 2004
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up studyMaria Patrizia Carrieri, François Raffi, Charlotte Lewden, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2009
Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort studyTristan Ferry, François Raffi, Fidéline Collin-Filleul, et al.
BMJ Open|November 27, 2012
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapyMaria Patrizia Carrieri, Camelia Protopopescu, Vincent Le Moing, et al.
Therapeutic Drug Monitoring|January 25, 2005
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohortXavier Duval, France Mentré, Claire Lamotte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 16, 2015
Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatmentCatherine Chirouze, Valérie Journot, Vincent Le Moing, et al.
Pageof 11